Overview
Founded in 2017, Catalina Genetics has become Australia’s equine cloning trailblazer. After perfecting the technology to successfully clone horses, and achieving an Australian first, the Catalina team invested in more R&D. The start-up went on to develop embryo sexing and in vitro fertilisation (IVF) using intracytoplasmic sperm injection (ICSI) for horses to offer a full suite of reproductive services to breeders.
Prime selection
Catalina Genetics’ mission was to pioneer cloning for horses in Australia and commercialise the process. Six years later, Catalina Genetics has expanded its range of services to become Australia’s most advanced equine reproduction centre. Through the strategic use of R&D capital and a deep commitment to innovation, the start-up is now expanding into cattle cloning and reproductive technology services, while eyeing new market opportunities overseas.
Leveraging cash flow
Catalina Genetics had sufficient capital to perfect its horse cloning technology. But without the booster of reinvesting successive Radium Advances, the start-up would not have been able to offer the range of novel animal reproductive services it does today.
“Radium Advances enabled us to leverage our available capital and double our R&D cash flow,” John says.
Using Radium Advances meant Catalina Genetics did not have the distraction of needing to raise capital. And its founding team could keep control of the business and make decisions readily.
Today Catalina Genetics is starting to grow its cattle offering within its suite of animal reproductive services and the business is about to open a new facility in England to serve its large customer base in the UK.
Download the case study to discover how Catalina Genetics reinvested several Radium Advances to fast-track its R&D program.
For more information, visit the Catalina Genetics website.
